Literature DB >> 16941687

Global challenges in liver disease.

Roger Williams1.   

Abstract

Immigration, cheap air travel, and globalization are all factors contributing to a worldwide spread of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. End-stage chronic liver disease (ESLD) as a result of co-infection with HBV/HCV is now the major cause of death for individuals who have been infected with the HIV virus. The high incidence of HCV infection in Egypt--the legacy left from the mass use of tartar emetic to eradicate schistosomiasis, as in other high prevalence areas--will take years to reduce. Steatohepatitis due to non-alcoholic fatty liver disease is developing into a new and major health problem as a result of rising levels of obesity in populations worldwide. Hepatic steatosis also has an adverse influence on the progression of other liver diseases including chronic HCV infection and alcoholic liver disease. In many countries, considerable public concern is on the rise due to increased levels of alcohol consumption adversely affecting younger and affluent age groups. With the rising prevalence of cirrhosis, primary hepatocellular carcinoma (HCC) is increasing in frequency as is that of primary intrahepatic cholangiocarcinoma. Finally, despite the successes of liver transplantation, many deserving patients are not getting transplants due to low levels of cadaver organ donation in many countries, thereby increasing pressures on the use of living donor liver transplantation. Only through a concerted effort from governments, health agencies, healthcare professionals at all levels, and the pharmaceutical industry can this grim outlook for liver disease worldwide be reversed.

Entities:  

Mesh:

Year:  2006        PMID: 16941687     DOI: 10.1002/hep.21347

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  264 in total

1.  Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment.

Authors:  Mazen Noureddin; Marc G Ghany
Journal:  Am J Gastroenterol       Date:  2010-10       Impact factor: 10.864

2.  Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.

Authors:  Daniel L Motola; Peter Caravan; Raymond T Chung; Bryan C Fuchs
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

Review 3.  Hepatic stellate cells and innate immunity in alcoholic liver disease.

Authors:  Yang-Gun Suh; Won-Il Jeong
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

4.  Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients.

Authors:  Samuel F Gilbert; Amr S Soliman; Mehdi Karkouri; Meaghen Quinlan-Davidson; Ashley Strahley; Mohab Eissa; Subhojit Dey; Ahmed Hablas; Ibrahim A Seifeldin; Mohamed Ramadan; Noureddine Benjaafar; Kathy Toy; Sofia D Merajver
Journal:  Breast Dis       Date:  2011

5.  Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes.

Authors:  Shubham Shrivastava; Amit Raychoudhuri; Robert Steele; Ranjit Ray; Ratna B Ray
Journal:  Hepatology       Date:  2011-01-10       Impact factor: 17.425

Review 6.  Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease.

Authors:  Hui Dong; Fu-Er Lu; Li Zhao
Journal:  Chin J Integr Med       Date:  2012-02-05       Impact factor: 1.978

Review 7.  Hepatic non-parenchymal cells: Master regulators of alcoholic liver disease?

Authors:  Wonhyo Seo; Won-Il Jeong
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

8.  Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up.

Authors:  Siu-Ka Mak; Ho-Kwan Sin; Kin-Yee Lo; Man-Wai Lo; Shuk-Fan Chan; Kwok-Chi Lo; Yuk-Yi Wong; Lo-Yi Ho; Ping-Nam Wong; Andrew K M Wong
Journal:  Clin Exp Nephrol       Date:  2017-01-12       Impact factor: 2.801

Review 9.  Viral hepatitis in HIV infection.

Authors:  Margaret James Koziel; Marion G Peters
Journal:  N Engl J Med       Date:  2007-04-05       Impact factor: 91.245

10.  Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver.

Authors:  N Obeng-Adjei; D K Choo; J Saini; J Yan; P Pankhong; A Parikh; J S Chu; D B Weiner
Journal:  Cancer Gene Ther       Date:  2012-10-05       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.